Bio-Techne touts study with ExoDx prostate test

By LabPulse.com staff writers

February 16, 2022 -- Bio-Techne is touting a new clinical study that indicates that its exosome-based, noninvasive urine prostate test, ExoDx Prostate test (EPI), correlates with post-prostatectomy pathology outcomes.

In men with an EPI score below 15.6, the test could prevent those at low risk from proceeding to radical prostatectomy, according to a study published January 27 in the World Journal of Urology.

To explore the applicability of the test for men with low-risk disease considering active surveillance, researchers tested 2,066 subjects. When EPI scores were evaluated for men classified as grade group 1 (GG1) on biopsy, those men who were upgraded to grade group 3 (≥ GG3) had significantly higher EPI scores compared to men who remained in GG1 after radical prostatectomy.

However, neither prostate-specific antigen blood testing nor any other risk calculators discriminated between these groups. In this cohort, zero cases were upgraded to ≥ GG3 when the EPI scores were below the cut-point of 15.6 resulting in a high negative predictive value (100%) for ruling out ≥ GG3, according to the company.

Bio-Techne launches multiplex spatial genomics assay
Bio-Techne has expanded its RNAscope in situ hybridization technology portfolio with the release of the new RNAscope HiPlex V2 assay for formalin-fixed,...
Bio-Techne teams up with Leica to bring RNAscope to Europe
Global life sciences firm Bio-Techne and pathology workflow software developer Leica Biosystems have launched Bio-Techne's RNAscope in situ hybridization...
Bio-Techne's prostate cancer test lands FDA breakthrough status
Bio-Techne's ExoDx Prostate IntelliScore liquid biopsy test for spotting aggressive prostate cancers has received the U.S. Food and Drug Administration's...

Copyright © 2022 LabPulse.com

Last Updated ls 2/16/2022 3:15:09 PM